AstraZeneca is working with DxS to commercialize a EGFR mutation test kit in Europe to identify the patient population most likely to benefit from treatment with non-small cell lung cancer drug Iressa. The company has announced no such plans in the US, where the FDA has restricted any new NSCLC patients from receiving the drug.
In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.
